Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?

被引：0
作者：
H. S. A. Tingen
A. Tubben
J. Bijzet
M. P. van den Berg
P. van der Meer
E. J. Houwerzijl
F. L. H. Muntinghe
P. A. van der Zwaag
A. W. J. M. Glaudemans
M. I. F. J. Oerlemans
C. Knackstedt
M. Michels
A. Hirsch
B. P. C. Hazenberg
R. H. J. A. Slart
H. L. A. Nienhuis
机构：
[1] University Medical Centre Groningen and Amyloidosis Centre of Expertise,Department of Nuclear Medicine and Molecular Imaging
[2] University Medical Centre Groningen and Amyloidosis Centre of Expertise,Department of Cardiology
[3] University Medical Centre Groningen and Amyloidosis Centre of Expertise,Department of Rheumatology & Clinical Immunology
[4] University Medical Centre Groningen and Amyloidosis Centre of Expertise,Department of Internal Medicine
[5] University Medical Centre Groningen and Amyloidosis Centre of Expertise,Department of Clinical Genetics
[6] University Medical Centre Utrecht,Department of Cardiology and Member of the European Reference Network for rare, low prevalence and complex diseases of the heart: ERN GUARD
[7] Cardiovascular Research Institute Maastricht (CARIM),Heart
[8] Maastricht University Medical Centre +,Department of Cardiology
[9] University Medical Centre Rotterdam,Department of Cardiology
[10] University Medical Centre Rotterdam,Department of Radiology and Nuclear Medicine
[11] University of Twente,Biomedical Photonic Imaging Group, Faculty of Science and Technology
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2024年 / 51卷
关键词：
ATTR-CM; ATTRv amyloidosis; Bone scintigraphy; Gene silencing; TTR stabilizers; Monitoring;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：681 / 690
页数：9
相关论文
共 140 条
  • [1] Adams D(2019)Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease Nat Rev Neurol 15 387-404
  • [2] Koike H(2018)Frequency of and prognostic significance of cardiac involvement at presentation in hereditary transthyretin-derived amyloidosis and the value of N-terminal Pro-B-type natriuretic peptide Am J Cardiol 121 107-112
  • [3] Slama M(2021)Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases Eur Heart J 42 1554-1568
  • [4] Coelho T(2016)Nonbiopsy diagnosis of cardiac transthyretin amyloidosis Circulation 133 2404-2412
  • [5] Klaassen SHC(2021)Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial and long-term extension study Eur J Heart Fail 23 277-285
  • [6] Tromp J(2020)Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis J Cardiac Fail 26 753-759
  • [7] Nienhuis HLA(2015)Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis Amyloid 22 79-83
  • [8] van der Meer P(2013)Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial JAMA 310 2658-21
  • [9] van den Berg MP(2018)Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis N Engl J Med 379 11-443
  • [10] Blokzijl H(2019)Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO study Circulation 139 431-58
12345678910